SCYNEXIS (SCYX)
NASDAQ:SCYX
SCYX Stock Chart & Stats
$0.66
-$0.06(-4.73%)
At close: 4:00 PM EST
$0.66
-$0.06(-4.73%)
Day’s Range― - ―
52-Week Range$0.57 - $1.31
Previous CloseN/A
Volume100.07K
Average Volume (3M)612.75K
Market Cap
$39.66M
Enterprise Value$20.57M
Total Cash (Recent Filing)$40.11M
Total Debt (Recent Filing)$2.17M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
May 18, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.25
Shares Outstanding44,663,834
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue1.00
Enterprise Value/Gross Profit1.00
Enterprise Value/Ebitda1.25
Forecast
1Y Price Target
$3.50Price Target Upside430.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$1.15M
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetLeverage reduction to ~$2.2M and a low debt-to-equity (~0.04) materially improves financial flexibility. With equity of $49.4M versus $59.0M in assets, the company is better positioned to fund development work and absorb setbacks, lowering near-term insolvency risk.
Extended Cash RunwayThe $40M PIPE provides multi-year funding visibility and includes institutional healthcare investors plus CEO participation. This reduces immediate financing pressure, enabling planned Phase 2 starts and program advancement without urgent dilutive raises over the next several years.
Strategic Pipeline ExpansionAcquiring SCY-770 diversifies SCYNEXIS beyond antifungals into a high-value rare disease (ADPKD) with orphan status and longer-term IP. A Phase 2 plan with an FDA-endorsed surrogate endpoint could enable accelerated pathways and materially alter growth prospects if clinical proof emerges.
Bears Say
Revenue VolatilityExtreme top-line swings across recent years signal reliance on episodic events or one-off factors rather than stable commercial traction. This inconsistent revenue profile undermines predictability of cash flow, complicates forecasting and increases execution risk for funding ongoing development.
Negative Free Cash FlowDespite improvement, persistent negative FCF means operations still consume cash and the business remains dependent on external financing to fund trials and commercialization. Continued burn risks further dilution or constrained program funding if clinical progress stalls.
Ongoing LossesSustained unprofitability and negative ROE erode shareholders' equity over time and limit the company's ability to self-finance growth. If operating losses persist, the strengthened balance sheet could be depleted, increasing reliance on dilutive capital raises to advance pipeline programs.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $0.56 and its highest was $1.31 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $39.66M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is May 18, 2026 which is in 43 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Mar 04, 2026. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.127 by $0.123.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.13.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 44,663,834 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.25 in its last earnings report, beating expectations of $0.127. Following the earnings report the stock price went up 2.194%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (430.30% Upside)
$3.50 (430.30% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.87%
12-Months-Change
Fundamentals
Return on Equity
-19.05%
Trailing 12-Months
Asset Growth
-34.88%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYX Stock 12 Month Forecast
Average Price Target
$3.50
▲(430.30% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
5.93% Insiders
12.58% Mutual Funds
5.89% Other Institutional Investors
71.90% Public Companies and
Individual Investors